KPV

Grade D: Preclinical or anecdotal only

TL;DR: KPV has no verified human evidence. The FDA explicitly stated it lacked human exposure data for any route of administration at the time of its compounding review. All published efficacy evidence comes from animal models and in vitro studies, primarily in murine models of inflammatory bowel disease and mucosal injury, where anti-inflammatory activity has been reported. Specific statistics or trial results circulating on commercial or vendor sources have not been verified against peer-reviewed publications or registered trial records and should not be treated as established. KPV's grade is D: no human evidence has been confirmed in the published or registered scientific literature.

Key Takeaways

Grade D: Preclinical or anecdotal only
Not FDA approved: Not FDA-approved; FDA noted absence of human exposure data in compounding review.
Compounding: The nomination to add KPV to the FDA 503A or 503B bulk-substances list was withdrawn; it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding.

KPV chemical structure — Structure via PubChem CID 13294447

Mechanism

Proposed to suppress pro-inflammatory signaling, in part via melanocortin receptor pathways, based on its structural derivation from the C-terminus of alpha-melanocyte-stimulating hormone.

Evidence

KPV has no verified human evidence. The FDA explicitly stated it lacked human exposure data for any route of administration at the time of its compounding review. All published efficacy evidence comes from animal models and in vitro studies, primarily in murine models of inflammatory bowel disease and mucosal injury, where anti-inflammatory activity has been reported. Specific statistics or trial results circulating on commercial or vendor sources have not been verified against peer-reviewed publications or registered trial records and should not be treated as established. KPV's grade is D: no human evidence has been confirmed in the published or registered scientific literature.

Safety and risks

Human safety data for KPV does not exist. Animal studies using oral administration did not identify serious safety signals in those models, but animal findings cannot be extrapolated to human injectable or systemic use without dedicated human safety trials. The FDA's finding of no human exposure data is the governing characterization of the evidence base. Long-term safety, immunogenicity, and dose-response effects in humans are entirely unknown. Compounded formulations are not subject to FDA manufacturing oversight, and purity of available preparations is unverified.

Interactions

No human pharmacokinetic or interaction data available.

Federal compounding status

Nomination withdrawn (was Category 2) as of 2026-06-02.

This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

The nomination to add KPV to the FDA 503A or 503B bulk-substances list was withdrawn; it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding.

Sources

KPV is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).